| Followers | 905 |
| Posts | 39659 |
| Boards Moderated | 7 |
| Alias Born | 03/22/2016 |
Friday, February 02, 2024 3:21:58 PM
CVKD....BEAUTIFUL PLAY...OUT AT 2 BUCKS BACK IN AT 1.10...LETS DO IT ALL OVER!!!
Recent CVKD News
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 04/06/2026 08:05:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/01/2026 11:40:36 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 04/01/2026 11:30:38 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2026 01:02:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/31/2026 12:55:07 PM
- Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting • GlobeNewswire Inc. • 03/31/2026 12:45:00 PM
- Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing • GlobeNewswire Inc. • 03/13/2026 12:35:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/12/2026 12:05:43 PM
- Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes • GlobeNewswire Inc. • 03/12/2026 12:00:00 PM
- Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th • GlobeNewswire Inc. • 03/10/2026 02:21:44 PM
- Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/24/2026 01:35:37 PM
- Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement • GlobeNewswire Inc. • 02/24/2026 01:30:00 PM
- Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference and VLX-1005 as a Potential Therapeutic Solution as the First and Only Selective 12-LOX Inhibitor • GlobeNewswire Inc. • 01/12/2026 01:00:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/02/2026 09:05:24 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/29/2025 09:25:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/23/2025 09:58:54 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/23/2025 09:56:48 PM
- Cadrenal Therapeutics to Conduct Partnering and Investor Meetings During the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026 • GlobeNewswire Inc. • 12/17/2025 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/16/2025 01:24:18 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/16/2025 01:21:37 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/16/2025 01:18:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2025 01:17:00 PM
